From: A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study
AEFI | Gender | Age group (years) | |||||||
---|---|---|---|---|---|---|---|---|---|
Female N = 3847 (%) | Male N = 2509 (%) | p value | 12–17 N = 233 (%) | 18–44 N = 3546 (%) | 45–64 N = 1864 (%) | 65–74 N = 312 (%) | > 75 N = 372 (%) | p value | |
Systemic AEFIs | |||||||||
 Fatigue | 1603 (41.7) | 1009 (40.2) | 0.251 | 57 (24.5) | 1579 (44.5) | 769 (41.3) | 114 (36.5) | 92 (24.7) | < 0.001* |
 General body pain | 1609 (41.8) | 969 (38.6) | 0.011* | 38 (16.3) | 1532 (43.2) | 761 (40.8) | 107 (34.3) | 131 (35.2) | < 0.001* |
 Headache | 1482 (38.5) | 859 (34.2) | 0.001* | 58 (24.9) | 1452 (40.9) | 691 (37.1) | 94 (30.1) | 42 (11.3) | < 0.001* |
 Fever | 1238 (32.2) | 840 (33.5) | 0.286 | 65 (27.9) | 1,248 (35.2) | 612 (32.8) | 72 (23.1) | 76 (20.4) |  < 0.001* |
 Chills | 1202 (31.2) | 706 (28.1) | 0.009* | 31 (13.3) | 1118 (31.5) | 602 (32.3) | 65 (20.8) | 87 (23.4) | < 0.001* |
 Nausea | 757 (19.7) | 290 (11.6) | < 0.001* | 29 (12.4) | 677 (19.1) | 281 (15.1) | 38 (12.2) | 21 (5.6) |  < 0.001* |
 Dyspnea | 308 (8.0) | 198 (7.9) | 0.887 | 17 (7.3) | 349 (9.8) | 116 (6.2) | 12 (3.8) | 12 (3.2) | < 0.001* |
 Abdominal pain | 323 (8.4) | 165 (6.6) | 0.008* | 19 (8.2) | 338 (9.5) | 108 (5.8) | 13 (4.2) | 10 (2.7) | < 0.001* |
 Diarrhea | 287 (7.5) | 168 (6.7) | 0.253 | 14 (6.0) | 279 (7.9) | 118 (6.3) | 25 (8.0) | 19 (5.1) | 0.102 |
 Cough | 260 (6.8) | 159 (6.3) | 0.535 | 13 (5.6) | 287 (8.1) | 92 (4.9) | 14 (4.5) | 13 (3.5) | < 0.001* |
 Dizziness | 240 (6.2) | 134 (5.3) | 0.141 | 41 (17.6) | 220 (6.2) | 85 (4.6) | 18 (5.8) | 10 (2.7) | < 0.001* |
 Vomiting | 247 (6.4) | 94 (3.7) | < 0.001* | 15 (6.4) | 202 (5.7) | 97 (5.2) | 12 (3.8) | 14 (3.8) | 0.428 |
Local AEFIs | |||||||||
 Injection site pain | 1687 (43.9) | 1020 (40.7) | 0.012* | 63 (27.0) | 1669 (47.1) | 765 (41.0) | 125 (40.1) | 78 (21.0) | < 0.001* |
 Injection site swelling | 424 (11.0) | 188 (7.5) | < 0.001* | 17 (7.3) | 380 (10.7) | 177 (9.5) | 26 (8.3) | 10 (2.7) | < 0.001* |
 Injection site erythema | 296 (7.7) | 113 (4.5) | < 0.001* | 8 (3.4) | 241 (6.8) | 128 (6.9) | 15 (4.8) | 15 (4.0) | 0.044* |